CANLI
Yükleniyor Veriler getiriliyor…
/ Makaleler / Scopus Detay
Scopus YÖKSİS Eşleşti

Protective effect of infliximab on ischemia/reperfusion-induced damage in rat kidney

Renal Failure · Ekim 2012

YÖKSİS DOI Eşleşmesi Bulundu

Bu Scopus makalesi YÖKSİS veritabanında da kayıtlı. Aşağıda YÖKSİS verilerini görebilirsiniz.

YÖKSİS Kayıtları
Protective Effect of Infliximab on Ischemia/Reperfusion-Induced Damage in Rat Kidney
RENAL FAİLURE · 2012 SCI
DOKTOR ÖĞRETİM ÜYESİ MERVE GÖKŞİN KARAASLAN TUNÇ →

Makale Bilgileri

DergiRenal Failure
Yayın TarihiEkim 2012
Cilt / Sayfa34 · 1144-1149
Özet Objective: To investigate the protective effect of infliximab on ischemiareperfusion (I/R) injury of the rat kidney. Methods: Twenty-eight male Wistar albino rats were divided into four groups: sham-operated, I/R, I/R with infliximab administered before ischemia [I/R infliximab (bi)], and I/R with infliximab administered before reperfusion [I/R infliximab (br)]. After a right nephrectomy to produce damage, the left renal vessels were occluded for 60 min, followed by 24-h reperfusion in rats. Changes in the rat kidney were observed by measuring the tissue levels of malondialdehyde (MDA), myeloperoxidase (MPO), glutathione (GSH), and superoxide dismutase (SOD) and by evaluating hematoxylineosin (H&E)-stained and periodic acidSchiff (PAS) sections. Results: The MDA and MPO levels in the I/R group were significantly higher than in the other groups (p < 0.05), and the SOD and GSH levels in the I/R infliximab (bi) and I/R infliximab (br) groups were significantly higher than in the I/R group (p < 0.05). However, histological examination revealed that the I/R infliximab (bi) group and the I/R infliximab (br) group had significantly fewer tubular changes and interstitial inflammatory cell infiltration than the I/R group. Conclusion: These results show that infliximab may protect against I/R injury in the rat I/R model. © 2012 Informa Healthcare USA, Inc.

Yazarlar (8)

1
Cemal Tasdemir
2
Seda Tasdemir
3
Nigar Vardi
ORCID: 0000-0003-0576-1696
4
Burhan Ates
ORCID: 0000-0001-6080-229X
5
Hakan Parlakpinar
ORCID: 0000-0001-9497-3468
6
Bulent Kati
7
Merve Gökşin Karaaslan
8
Ahmet Acet

Anahtar Kelimeler

Infliximab Ischemiareperfusion Renal

Kurumlar

Inönü Üniversitesi
Malatya Turkey
Medical Faculty
Malatya Turkey

Metrikler

34
Atıf
8
Yazar
3
Anahtar Kelime